{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-cell+Acute+Lymphoblastic+Leukemia&page=14", "query": { "condition": "T-cell Acute Lymphoblastic Leukemia", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 769, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-cell+Acute+Lymphoblastic+Leukemia&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=T-cell+Acute+Lymphoblastic+Leukemia&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T11:15:50.358Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00082888", "title": "Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Nodal Marginal Zone Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Tipifarnib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2004-03-24", "completion_date": "2017-07-05", "has_results": true, "last_update_posted_date": "2020-04-13", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 2, "location_summary": "Iowa City, Iowa • Rochester, Minnesota", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082888" }, { "nct_id": "NCT00651261", "title": "Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin", "type": "DRUG" }, { "name": "midostaurin", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "dexamethasone acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 717, "start_date": "2008-04", "completion_date": null, "has_results": true, "last_update_posted_date": "2021-08-18", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 170, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00651261" }, { "nct_id": "NCT07819396", "title": "Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Biphenotypic Leukemia", "Acute Leukemia", "Acute Leukemia of Ambiguous Lineage", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Undifferentiated Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Burkitt Leukemia", "Burkitt Lymphoma", "Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Lymphoblastic Lymphoma", "Mast Cell Leukemia", "Mixed Phenotype Acute Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Allogeneic CD34+-enriched and CD45RA-depleted PBSCs", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 52, "start_date": "2027-01-01", "completion_date": "2031-06-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07819396" }, { "nct_id": "NCT02746952", "title": "Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "UCART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 25, "start_date": "2016-08-01", "completion_date": "2020-07-28", "has_results": false, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02746952" }, { "nct_id": "NCT00450983", "title": "Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "muromonab-CD3", "type": "BIOLOGICAL" }, { "name": "natural killer cell therapy", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 1, "start_date": "2006-12", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2017-05-24", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450983" }, { "nct_id": "NCT00025662", "title": "Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft vs Host Disease", "Myelodysplastic Syndromes", "Leukemia", "Leukemia, Myeloid", "Leukemia, Myelomonocytic, Chronic", "Leukemia, Lymphocytic", "Lymphoma", "Lymphoma, Mantle-cell", "Lymphoma, Non-Hodgkin", "Hodgkin Disease" ], "interventions": [ { "name": "RFT5-SMPT-dgA", "type": "DRUG" }, { "name": "Isolex system", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 23, "start_date": "2001-05", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025662" }, { "nct_id": "NCT02374333", "title": "Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphocytic Leukemia", "Diffuse Large Cell Lymphoma" ], "interventions": [ { "name": "huCART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "24 Years", "sex": "ALL", "summary": "1 Year to 24 Years" }, "enrollment_count": 81, "start_date": "2014-03-25", "completion_date": "2021-09-02", "has_results": false, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02374333" }, { "nct_id": "NCT02793544", "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Chronic Lymphocytic Leukemia (CLL)", "Chemotherapy-sensitive Lymphoma", "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma", "Acute Myelogenous Leukemia (AML)", "Acute Biphenotypic Leukemia (ABL)", "Acute Undifferentiated Leukemia (AUL)" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy on Day -1", "type": "RADIATION" }, { "name": "Infusion of non-T-cell depleted bone marrow on Day 0", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1", "type": "DRUG" }, { "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1", "type": "RADIATION" }, { "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -6 and -5", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -2 and -1", "type": "DRUG" }, { "name": "Pre-HCT Mesna on Days -5 and -4", "type": "DRUG" }, { "name": "Post-HCT Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 80, "start_date": "2016-12", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-08-06", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 11, "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02793544" }, { "nct_id": "NCT00501826", "title": "Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T Acute Lymphoblastic Leukemia", "T Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 160, "start_date": "2007-07-11", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00501826" }, { "nct_id": "NCT00080925", "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2004-02", "completion_date": "2010-12", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-17T11:15:50.358Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080925" } ] }